TriSalus Life Sciences, Inc. Share Price

TriSalus Life Sciences, Inc. Share Price

NASDAQ: TLSI | Micro Cap
$3.70
-$0.16 (-4.15%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

TriSalus Life Sciences, Inc. Stock Performance

Open
$3.83
Prev. Close
$3.86
Circuit Range
N/A
Day Range
$3.69 - $3.85
Year Range
$2.23 - $7.83
Volume
3,838
Average Traded
$3.74

TriSalus Life Sciences, Inc. Share Price Today

As of 31 October 2026, TriSalus Life Sciences, Inc.'s share price is $3.70. The stock opened at $3.83, compared to its previous close of $3.86. During today's trading session, TriSalus Life Sciences, Inc.'s share price traded between $3.69 and $3.85, with an average price of $3.77. Over the past 52 weeks, the stock has recorded a high of $7.83 and a low of $2.23. In terms of performance, TriSalus Life Sciences, Inc.'s share price has declined by 14.05% over the last six months and is down 21.78% on a year-on-year basis.

TriSalus Life Sciences, Inc. Share Price Chart

Line chart of the TriSalus Life Sciences, Inc. price trend over the selected period. The price fell overall, ranging from 3.66 to 3.87, ending at 3.70.
$3.69$3.85
L
Show Current Price
H

TriSalus Life Sciences, Inc. Stock Fundamentals & Key Indicators

Market Cap
$140.22M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.95
Revenue (TTM)
$45.15B
Return On Equity (TTM)
-895.80%
Profit Margin
-154.35%
Debt to Equity
5.05
Quarterly Earnings Growth YoY
77.73%

TriSalus Life Sciences, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$11.57$13.21$8.90$11.41
Net Profit-$41.27-$9.75$1.54-$9.19
Net Profit Margin-356.70%-73.81%17.30%-80.54%
Income ChangeN/A76.38%115.79%-696.75%

TriSalus Life Sciences, Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$18.51$29.43$45.15
Net Profit-$63.60-$33.23-$69.69
Net Profit Margin-343.60%-112.91%-154.35%
Income ChangeN/A47.75%-109.72%

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

TriSalus Life Sciences, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$4.20
$3.71
-14.22%
Sep 2026
$5.09
$4.33
-12.45%
Aug 2026
$4.56
$4.94
+8.81%
Jul 2026
$4.53
$4.54
-0.33%
Jun 2026
$3.33
$4.55
+33.19%
May 2026
$4.34
$3.42
-20.56%
Apr 2026
$4.15
$4.30
+7.36%
Mar 2026
$5.02
$4.01
-20.44%
Feb 2026
$4.86
$5.04
+1.41%
Jan 2026
$6.95
$4.97
-28.59%
Dec 2025
$6.75
$6.96
+1.46%
Nov 2025
$4.66
$6.86
+45.03%

TLSI Share Price FAQs